Dr. Alexis N. Simpkins is an assistant professor of neurology and a vascular neurologist who focuses on cutting-edge stroke research, novel acute stroke therapies, stroke prevention and advanced brain imaging. Dr. Simpkins is an active member in the American Heart Association and Director of the CREST Initiative for stroke trainee and fellow research and career development in the Vascular Neurology Division.
Areas of Expertise (5)
Acute Ischemic Stroke
Stroke Imaging Techniques
Media Appearances (4)
Overview of secondary prevention of ischemic stroke
The management of treatable risk factors and common mechanisms of brain ischemia is important for reducing the risk of ischemic stroke. This topic will review the risk factors for stroke, with a focus on secondary prevention in patients who have a history of transient ischemic attack or ischemic stroke or are considered to have a high risk of ischemic stroke due to the presence of coronary heart disease or diabetes.
1,000 inspiring Black scientists in America
Cell Mentor online
Maya Angelou once said, "We delight in the beauty of the butterfly, but rarely admit the changes it has gone through to achieve that beauty.” This can be said for Black culture in its entirety. Black culture is the archetype for innovation, distinction, creativity, intelligence, spirituality, and healing. Black culture is distinct, and it has a heavy influence on American and global cultures. Likewise, Black talent is both ubiquitous and abundant, but the excellence of Black people is often obscured.
AFib patients do best on a DOAC started 7-10 days post stroke
MDedge: Emergency Medicine online
When a patient with atrial fibrillation (AFib) has a cardioembolic stroke, the best blood thinner to start may be a direct-acting oral anticoagulant (DOAC), possibly beginning 7-10 days after the index stroke, according to an analysis of 90-day, observational outcomes data from nearly 1,300 patients.
Success Stories: Alexis Simpkins
National Institute of Neurological Disorders and Stroke online
My interest in research was sparked as an undergrad during a summer program at the Medical College of Georgia. I worked on a project in Dr. Susan Fagan’s lab to develop an assay that would allow blood to be accurately measured in an animal model of stroke, which could be used to assess the effectiveness of drugs being studied in the pre-clinical setting. Once I learned how medical research could have such a broad impact on patient care, I could not envision a career without incorporating both clinical care and medical research. This experience set me on my path to becoming a vascular neurologist, a path that was solidified when my father had a stroke that affected his speech. Seeing first-hand how the ramifications of a stroke can drastically change a person’s life greatly affirmed my choice to become a neurologist.
Optimal Patient Selection for EVT Beyond 6 Hours After Symptom OnsetJAMA Neurology
Alexis N. Simpkins
Current guidelines recommend endovascular thrombectomy (EVT) beyond 6 hours from stroke onset in patients with an imaging profile mismatch between the clinical defect and the size of early infarction (clinical mismatch) or between the size of the perfusion lesion and the size of early infarction (target–perfusion mismatch). Significant uncertainty persists regarding the optimal imaging approach for selecting patients for EVT in this patient population. To help address this uncertainty, the authors of this study used data from the AURORA database, which includes pooled patient-level data from six randomized clinical trials (DAWN, DEFUSE 3, REVASCAT, ESCAPE, RESILIENT, and POSITIVE).
Adapting Clinical Practice of Thrombolysis for Acute Ischemic Stroke Beyond 4.5 Hours: A Review of the LiteratureJournal of Stroke & Cerebrovascular Diseases
Alexis N. Simpkins, et al.
Several clinical trials have demonstrated that advanced neuroimaging can select patients for recanalization therapy in an extended time window. The favorable functional outcomes and safety profile of these studies have led to the incorporation of neuroimaging in endovascular treatment guidelines, and most recently, also extended to decision making on thrombolysis. Two randomized clinical trials have demonstrated that patients who are not amenable to endovascular thrombectomy within 4.5 hours from symptoms discovery or beyond 4.5 hours from the last-known-well time may also be safely treated with intravenous thrombolysis and have a clinical benefit above the risk of safety concerns.